title: Infant botulism in Australia: availability of human botulinum antitoxin for treatment.
abstract: We report the first Australian case of treatment of infant botulism with a human botulinum antitoxin developed in the United States by the California Department of Public Health. Our patient's clinical improvement was rapid, and although the product is expensive, cost-analysis supports the economical viability of its use. In future cases of suspected infant botulism, we recommend that Australian clinicians promptly obtain and administer this antitoxin to their patient.
authors.affiliation: Paediatric Infection Management Service, Mater Children's Hospital, Brisbane, QLD, Australia. meryta.may@mater.org.au
authors.forename: Meryta L A
authors.initials: ML
authors.lastname: May
authors.forename: Michael A
authors.initials: MA
authors.lastname: Corkeron
authors.forename: Mark
authors.initials: M
authors.lastname: Stretton
mesh_terms: D001315:Australia; D001906:Botulism / Q000175:diagnosis* / Q000188:drug therapy*; D002140:California; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant
chemical_list: D007136:Immunoglobulins; D007155:Immunologic Factors; C068584:botulism immune globulin